Acerus Announces Voting Results for the 2016 Annual General Meeting

TORONTO--()--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the voting results from its Annual General Meeting held on June 20, 2016 in Toronto, Ontario. The total number of shares represented in person or by proxy at the meeting was 126,757,709, representing 59.48% of the total issued and outstanding Acerus shares.

Election of Directors

The five (5) candidates nominated for election to the Acerus Board of Directors and listed in the Company's Management Information Circular, dated May 13, 2016, were elected by a majority of the shareholders present in person or represented by proxy at the meeting. The voting results are as follows:

       
Name     Votes For (%)     Votes Withheld (%)
Norma Beauchamp     119,320,447 (96.17%)     4,757,250 (3.83%)
Borys Chabursky     119,244,720 (96.10%)     4,832,977 (3.90%)
Stephen Gregory     119,136,720 (96.02%)     4,940,977 (3.98%)
Ian Ihnatowycz     119,197,932 (96.07%)     4,879,765 (3.93%)
Tom Rossi     118,941,220 (95.86%)     5,136,477 (4.14%)
 

Appointment of Auditors

Acerus also announced today that its shareholders have approved the re-appointment of PricewaterhouseCoopers LLP as the Auditor of Acerus to hold office until the next annual meeting of shareholders.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.

Acerus markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing an Acerus licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and available in the United States for replacement therapy in adult males diagnosed with hypogonadism. GYNOFLOR™, a product licensed to Acerus in Canada by Medinova AG and approved in 39 countries worldwide, is an ultra-low dose vaginal estrogen therapy with the addition of lactobacillus, for the treatment of atrophic vaginitis, certain vaginal infections and/or to restore a healthy vaginal environment. TEFINA™, a ‘use as required’ nasal testosterone gel, is an Acerus drug development candidate aimed at addressing a significant unmet need for women with female sexual dysfunction.

For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Contacts

Acerus Pharmaceuticals Corporation
Tiana DiMichele, 416-679-0822
Director, Marketing & Communications
tdimichele@aceruspharma.com

Contacts

Acerus Pharmaceuticals Corporation
Tiana DiMichele, 416-679-0822
Director, Marketing & Communications
tdimichele@aceruspharma.com